522 related articles for article (PubMed ID: 21764800)
1. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
[TBL] [Abstract][Full Text] [Related]
2. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S
Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479
[TBL] [Abstract][Full Text] [Related]
3. Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.
Cullinane C; Waldeck KL; Binns D; Bogatyreva E; Bradley DP; de Jong R; McArthur GA; Hicks RJ
Nucl Med Biol; 2014 Feb; 41(2):148-54. PubMed ID: 24332383
[TBL] [Abstract][Full Text] [Related]
4. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
Waldherr C; Mellinghoff IK; Tran C; Halpern BS; Rozengurt N; Safaei A; Weber WA; Stout D; Satyamurthy N; Barrio J; Phelps ME; Silverman DH; Sawyers CL; Czernin J
J Nucl Med; 2005 Jan; 46(1):114-20. PubMed ID: 15632041
[TBL] [Abstract][Full Text] [Related]
5. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
[TBL] [Abstract][Full Text] [Related]
6. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
[TBL] [Abstract][Full Text] [Related]
7. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.
Wang H; Zhang J; Tian J; Qu B; Li T; Chen Y; Liu J; Wang S
J Nucl Med; 2009 Nov; 50(11):1857-64. PubMed ID: 19837754
[TBL] [Abstract][Full Text] [Related]
8. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
[TBL] [Abstract][Full Text] [Related]
9. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
10. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC
J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of [
Jiang H; Zhang R; Jiang H; Zhang M; Guo W; Feng G; Pan W; Xu H; Wang S
Nucl Med Biol; 2019; 72-73():36-44. PubMed ID: 31330410
[TBL] [Abstract][Full Text] [Related]
12. Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging.
Habibollahi P; van den Berg NS; Kuruppu D; Loda M; Mahmood U
J Nucl Med; 2013 Feb; 54(2):252-8. PubMed ID: 23376854
[TBL] [Abstract][Full Text] [Related]
13. Imaging proliferation in human leukemia-tumor bearing mice with (18)F-FLT: Comparison with (18)F-FDG PET.
Lu L; Jiang L; Guan H; Gao Y; Lu H
Hell J Nucl Med; 2012; 15(3):206-9. PubMed ID: 23106052
[TBL] [Abstract][Full Text] [Related]
14. (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.
Brepoels L; Stroobants S; Verhoef G; De Groot T; Mortelmans L; De Wolf-Peeters C
J Nucl Med; 2009 Jul; 50(7):1102-9. PubMed ID: 19525456
[TBL] [Abstract][Full Text] [Related]
15. Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by
Iommelli F; De Rosa V; Terlizzi C; Monti M; Panico M; Fonti R; Del Vecchio S
Clin Cancer Res; 2018 Jul; 24(13):3126-3136. PubMed ID: 29618618
[No Abstract] [Full Text] [Related]
16. Fluorodeoxyglucose-based positron emission tomography imaging to monitor drug responses in solid tumors.
Newbold A; Martin BP; Cullinane C; Bots M
Cold Spring Harb Protoc; 2014 Oct; 2014(10):pdb.prot082529. PubMed ID: 25275109
[TBL] [Abstract][Full Text] [Related]
17. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.
Apisarnthanarax S; Alauddin MM; Mourtada F; Ariga H; Raju U; Mawlawi O; Han D; Bornmann WG; Ajani JA; Milas L; Gelovani JG; Chao KS
Clin Cancer Res; 2006 Aug; 12(15):4590-7. PubMed ID: 16899606
[TBL] [Abstract][Full Text] [Related]
18. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
19. Predictive Value of Early-Stage Uptake of 3'-Deoxy-3'-18F-Fluorothymidine in Cancer Cells Treated with Charged Particle Irradiation.
Lin C; Kume K; Mori T; Martinez ME; Okazawa H; Kiyono Y
J Nucl Med; 2015 Jun; 56(6):945-50. PubMed ID: 25766892
[TBL] [Abstract][Full Text] [Related]
20. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]